Profile data is unavailable for this security.
About the company
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
- Revenue in SEK (TTM)13.70m
- Net income in SEK-13.04m
- Incorporated2014
- Employees2.00
- LocationElicera Therapeutics ABWorld Trade Center Goteborg,Massans gata 10, van 7GOETEBORG 412 51SwedenSWE
- Phone+46 703319051
- Websitehttps://www.elicera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dare Bioscience Inc | 247.07k | -155.82m | 216.75m | 21.00 | -- | 8.29 | -- | 877.27 | -1.92 | -1.92 | 0.0029 | 0.2052 | 0.0011 | -- | 0.0624 | 1,318.57 | -71.56 | -91.64 | -241.96 | -243.93 | 127.70 | -- | -63,069.55 | -1,024.05 | -- | -156.39 | 0.7177 | -- | -99.65 | -- | 86.56 | -- | -- | -- |
| Brooks Laboratories Ltd | 87.54m | 21.29m | 220.04m | 323.00 | 10.36 | -- | 9.64 | 2.51 | 7.32 | 7.32 | 30.45 | -- | -- | -- | -- | 2,750,638.00 | -- | -14.21 | -- | -23.39 | 38.75 | 25.99 | 24.31 | -25.22 | -- | -- | -- | -- | 3.86 | 3.45 | 49.13 | -- | -18.61 | -- |
| Ikapharmindo Putramas Tbk PT | 201.07m | -14.72m | 221.50m | 994.00 | -- | 1.95 | -- | 1.10 | -16.48 | -16.48 | 225.13 | 127.12 | 0.8121 | 3.63 | 1.74 | 362,592,000.00 | -5.94 | -- | -10.96 | -- | 43.12 | -- | -7.32 | -- | 1.14 | -1.34 | 0.444 | -- | -6.59 | -- | -67.30 | -- | -- | -- |
| Vaidya Sane Ayurved Laboratories Ltd | 96.55m | 8.59m | 223.90m | 636.00 | 27.94 | 3.35 | 16.29 | 2.32 | 7.73 | 7.73 | 85.76 | 64.41 | 1.27 | 4.62 | 15.21 | -- | 11.32 | 7.04 | 13.25 | 9.52 | 83.84 | 73.31 | 8.91 | 4.29 | 2.32 | 84.89 | 0.0092 | -- | -9.55 | 3.61 | 260.35 | -- | 17.02 | -- |
| Magle Chemoswed Holding AB | 292.44m | -26.60m | 225.08m | 144.00 | -- | 0.4233 | 8.12 | 0.7697 | -1.29 | -1.29 | 14.56 | 25.75 | 0.3085 | -0.0596 | 8.14 | 1,989,374.00 | -2.81 | 2.43 | -3.45 | 3.45 | 102.66 | 88.63 | -9.09 | 4.76 | 0.8205 | -0.1043 | 0.3887 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
| Sat Kartar Life Ltd | -9.85bn | -9.85bn | 225.73m | 922.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 21.07 | -- | 34.79 | -- | 93.36 | -- | 4.50 | -- | -- | -- | 5.39 | 27.37 | 56.31 | 55.66 | 117.33 | 39.27 | -- |
| Elicera Therapeutics AB | 13.70m | -13.04m | 228.12m | 2.00 | -- | 7.44 | -- | 16.66 | -0.3434 | -0.3434 | 0.3712 | 0.6314 | 0.4004 | -- | 9.61 | 6,848,050.00 | -38.14 | -42.99 | -48.58 | -55.48 | -- | -- | -95.24 | -345.69 | -- | -- | 0.00 | -- | -36.52 | -- | 1.75 | -- | -- | -- |
| Vitura Health Ltd | 783.01m | 20.71m | 230.10m | 119.00 | 10.19 | 0.7556 | 6.87 | 0.2939 | 0.0054 | 0.0054 | 0.2034 | 0.0728 | 1.69 | 16.43 | 10.46 | -- | 4.11 | 12.75 | 5.72 | 17.62 | 27.21 | 30.97 | 2.43 | 6.06 | 1.05 | 9.50 | 0.2009 | -- | 0.1341 | 298.23 | -5.35 | -- | 129.38 | -- |
| Little Green Pharma Ltd | 243.00m | 36.96m | 231.54m | -- | 6.20 | 0.4264 | 3.78 | 0.9528 | 0.0194 | 0.0194 | 0.1268 | 0.2814 | 0.4262 | 0.8199 | 14.01 | -- | 6.48 | -- | 7.09 | -- | 67.46 | -- | 15.21 | -- | 0.8728 | -4.71 | 0.0541 | -- | 43.67 | -- | 140.77 | -- | -- | -- |
| Extrawell Pharmaceutical Holdings Ltd | 60.10m | -385.74m | 235.80m | 161.00 | -- | 0.2314 | -- | 3.92 | -0.1351 | -0.1352 | 0.0219 | 0.3501 | 0.0422 | 10.54 | 5.89 | 322,975.50 | -27.00 | 3.07 | -28.13 | 3.21 | 42.41 | 47.65 | -640.53 | 59.77 | 13.00 | -0.037 | 0.146 | -- | -6.21 | -6.50 | 236.70 | 21.75 | 80.07 | -- |
| Medicus Pharma Ltd | -892.26bn | -892.26bn | 237.53m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0434 | -- | -- | -- | -- | -- | -361.95 | -- | -- | -- | -- | -- | -- | -- | -- | 1.13 | -- | -- | -- | -109.90 | -- | -- | -- |
